{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:49:07Z","timestamp":1790858947486,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cytarabine (AraC) represents the most effective single agent treatment for AML. Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we show that the CHK1 inhibitor (CHK1i) GDC-0575 enhances AraC-mediated killing of AML cells both in vitro and in vivo, thus abrogating any potential chemoresistance mechanisms involving DNA repair. Importantly, this combination of drugs does not affect normal long-term hematopoietic stem\/progenitors. Moreover, the addition of CHK1i to AraC does not generate de novo mutations and in patients\u2019 samples where AraC is mutagenic, addition of CHK1i appears to eliminate the generation of mutant clones. Finally, we observe that persistent residual leukemic cells are quiescent and can become responsive to the treatment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration. This drug combination (AraC+CHK1i+G-CSF) will open the doors for a more efficient treatment of AML in the clinic.<\/jats:p>","DOI":"10.1038\/s41467-017-01834-4","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T11:17:00Z","timestamp":1510831020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia"],"prefix":"10.1038","volume":"8","author":[{"given":"Alessandro","family":"Di Tullio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-7364","authenticated-orcid":false,"given":"Kevin","family":"Rouault-Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Abarrategi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Grey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aengus","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Blackwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4735-5226","authenticated-orcid":false,"given":"Dominique","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"1834_CR1","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1182\/blood-2005-01-0178","volume":"106","author":"MS Tallman","year":"2005","unstructured":"Tallman, M. S., Gilliland, D. G. & Rowe, J. M. Drug therapy for acute myeloid leukemia. Blood 106, 1154\u20131163 (2005).","journal-title":"Blood"},{"key":"1834_CR2","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1016\/j.clinthera.2009.11.017","volume":"31","author":"T Robak","year":"2009","unstructured":"Robak, T. & Wierzbowska, A. Current and emerging therapies for acute myeloid leukemia. Clin. Ther. 31, 2349\u20132370 (2009).","journal-title":"Clin. Ther."},{"key":"1834_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1034\/j.1600-0609.2002.02785.x","volume":"69","author":"MJ Veuger","year":"2002","unstructured":"Veuger, M. J., Honders, M. W., Willemze, R. & Barge, R. M. Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia. Eur. J. Haematol. 69, 171\u2013178 (2002).","journal-title":"Eur. J. Haematol."},{"key":"1834_CR4","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1158\/0008-5472.CAN-07-5528","volume":"68","author":"J Cai","year":"2008","unstructured":"Cai, J. et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 68, 2349\u20132357 (2008).","journal-title":"Cancer Res."},{"key":"1834_CR5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1182\/blood.V99.4.1373","volume":"99","author":"MJ Veuger","year":"2002","unstructured":"Veuger, M. J., Heemskerk, M. H., Honders, M. W., Willemze, R. & Barge, R. M. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells. Blood 99, 1373\u20131380 (2002).","journal-title":"Blood"},{"key":"1834_CR6","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","volume":"21","author":"H Zhao","year":"2001","unstructured":"Zhao, H. & Piwnica-Worms, H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell Biol. 21, 4129\u20134139 (2001).","journal-title":"Mol. Cell Biol."},{"key":"1834_CR7","doi-asserted-by":"publisher","first-page":"18641","DOI":"10.1074\/jbc.M313536200","volume":"279","author":"D Loegering","year":"2004","unstructured":"Loegering, D. et al. Rad9 protects cells from topoisomerase poison-induced cell death. J. Biol. Chem. 279, 18641\u201318647 (2004).","journal-title":"J. Biol. Chem."},{"key":"1834_CR8","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1182\/blood-2004-09-3523","volume":"106","author":"RA Mesa","year":"2005","unstructured":"Mesa, R. A. et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 106, 318\u2013327 (2005).","journal-title":"Blood"},{"key":"1834_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4161\/cc.4.1.1299","volume":"4","author":"SH Cho","year":"2005","unstructured":"Cho, S. H., Toouli, C. D., Fujii, G. H., Crain, C. & Parry, D. Chk1 is essential for tumor cell viability following activation of the replication checkpoint. Cell Cycle 4, 131\u2013139 (2005).","journal-title":"Cell Cycle"},{"key":"1834_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","volume":"16","author":"Y Dai","year":"2010","unstructured":"Dai, Y. & Grant, S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16, 376\u2013383 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1834_CR11","first-page":"1065","volume":"61","author":"Z Shi","year":"2001","unstructured":"Shi, Z. et al. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res. 61, 1065\u20131072 (2001).","journal-title":"Cancer Res."},{"key":"1834_CR12","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1126\/science.1083430","volume":"300","author":"L Zou","year":"2003","unstructured":"Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542\u20131548 (2003).","journal-title":"Science"},{"key":"1834_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.dnarep.2009.04.023","volume":"8","author":"P Zegerman","year":"2009","unstructured":"Zegerman, P. & Diffley, J. F. DNA replication as a target of the DNA damage checkpoint. DNA Repair 8, 1077\u20131088 (2009).","journal-title":"DNA Repair"},{"key":"1834_CR14","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.dnarep.2007.02.015","volume":"6","author":"RD Paulsen","year":"2007","unstructured":"Paulsen, R. D. & Cimprich, K. A. The ATR pathway: fine-tuning the fork. DNA Repair 6, 953\u2013966 (2007).","journal-title":"DNA Repair"},{"key":"1834_CR15","doi-asserted-by":"publisher","first-page":"ra90","DOI":"10.1126\/scisignal.aac9704","volume":"9","author":"L David","year":"2016","unstructured":"David, L. et al. CHK1 as a therapeutic target to bypass chemoresistance in AML. Sci. Signal. 9, ra90 (2016).","journal-title":"Sci. Signal."},{"key":"1834_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.4161\/cc.3.9.1080","volume":"3","author":"L Carrassa","year":"2004","unstructured":"Carrassa, L., Broggini, M., Erba, E. & Damia, G. Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 3, 1177\u20131181 (2004).","journal-title":"Cell Cycle"},{"key":"1834_CR17","first-page":"5843","volume":"61","author":"Y Hirose","year":"2001","unstructured":"Hirose, Y., Berger, M. S. & Pieper, R. O. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 61, 5843\u20135849 (2001).","journal-title":"Cancer Res."},{"key":"1834_CR18","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.1158\/1078-0432.CCR-08-0304","volume":"14","author":"M Ganzinelli","year":"2008","unstructured":"Ganzinelli, M. et al. Checkpoint kinase 1 down\u2212regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. Clin. Cancer Res. 14, 5131\u20135141 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1834_CR19","first-page":"5743","volume":"62","author":"Q Yu","year":"2002","unstructured":"Yu, Q. et al. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 62, 5743\u20135748 (2002).","journal-title":"Cancer Res."},{"key":"1834_CR20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1124\/mol.105.012716","volume":"68","author":"LM Karnitz","year":"2005","unstructured":"Karnitz, L. M. et al. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol. Pharmacol. 68, 1636\u20131644 (2005).","journal-title":"Mol. Pharmacol."},{"key":"1834_CR21","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.1158\/1078-0432.CCR-12-0961","volume":"18","author":"EL Schenk","year":"2012","unstructured":"Schenk, E. L. et al. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro. Clin. Cancer Res. 18, 5364\u20135373 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1834_CR22","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1158\/1535-7163.MCT-12-0902","volume":"12","author":"Y Dai","year":"2013","unstructured":"Dai, Y. et al. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol. Cancer Ther. 12, 878\u2013889 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"1834_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jsbmb.2015.08.023","volume":"164","author":"X Wang","year":"2016","unstructured":"Wang, X., Harrison, J. S. & Studzinski, G. P. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination. J. Steroid Biochem. Mol. Biol. 164, 72\u201378 (2016).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"1834_CR24","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1182\/blood-2005-08-3351","volume":"107","author":"D Sampath","year":"2006","unstructured":"Sampath, D. et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107, 2517\u20132524 (2006).","journal-title":"Blood"},{"key":"1834_CR25","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/leu.2014.284","volume":"29","author":"SE Fordham","year":"2015","unstructured":"Fordham, S. E., Cole, M., Irving, J. A. & Allan, J. M. Cytarabine preferentially induces mutation at specific sequences in the genome which are identifiable in relapsed acute myeloid leukaemia. Leukemia 29, 491\u2013494 (2015).","journal-title":"Leukemia"},{"key":"1834_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1038\/sj.leu.2402608","volume":"16","author":"M Konopleva","year":"2002","unstructured":"Konopleva, M. et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16, 1713\u20131724 (2002).","journal-title":"Leukemia"},{"key":"1834_CR27","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1182\/blood-2009-05-224030","volume":"115","author":"F Lassailly","year":"2010","unstructured":"Lassailly, F., Griessinger, E. & Bonnet, D. \u201cMicroenvironmental contaminations\u201d induced by fluorescent lipophilic dyes used for noninvasive in vitro and in vivo cell tracking. Blood 115, 5347\u20135354 (2010).","journal-title":"Blood"},{"key":"1834_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.5966\/sctm.2013-0166","volume":"3","author":"E Griessinger","year":"2014","unstructured":"Griessinger, E. et al. A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl. Med. 3, 520\u2013529 (2014).","journal-title":"Stem Cells Transl. Med."},{"key":"1834_CR29","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood.V86.10.3745.bloodjournal86103745","volume":"86","author":"QL Hao","year":"1995","unstructured":"Hao, Q. L., Shah, A. J., Thiemann, F. T., Smogorzewska, E. M. & Crooks, G. M. A functional comparison of CD34+ CD38- cells in cord blood and bone marrow. Blood 86, 3745\u20133753 (1995).","journal-title":"Blood"},{"key":"1834_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10616-014-9796-y","volume":"67","author":"A Hordyjewska","year":"2015","unstructured":"Hordyjewska, A., Popiolek, L. & Horecka, A. Characteristics of hematopoietic stem cells of umbilical cord blood. Cytotechnology 67, 387\u2013396 (2015).","journal-title":"Cytotechnology"},{"key":"1834_CR31","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood.V89.7.2233","volume":"89","author":"LB To","year":"1997","unstructured":"To, L. B., Haylock, D. N., Simmons, P. J. & Juttner, C. A. The biology and clinical uses of blood stem cells. Blood 89, 2233\u20132258 (1997).","journal-title":"Blood"},{"key":"1834_CR32","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1607","volume":"28","author":"Y Saito","year":"2010","unstructured":"Saito, Y. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat. Biotechnol. 28, 275\u2013280 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1834_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","volume":"125","author":"G Ossenkoppele","year":"2015","unstructured":"Ossenkoppele, G. & Lowenberg, B. How I treat the older patient with acute myeloid leukemia. Blood 125, 767\u2013774 (2015).","journal-title":"Blood"},{"key":"1834_CR34","doi-asserted-by":"publisher","first-page":"ra91","DOI":"10.1126\/scisignal.aad8243","volume":"9","author":"I Morgado-Palacin","year":"2016","unstructured":"Morgado-Palacin, I. et al. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Sci. Signal. 9, ra91 (2016).","journal-title":"Sci. Signal."},{"key":"1834_CR35","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","volume":"18","author":"JE Karp","year":"2012","unstructured":"Karp, J. E. et al. Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias. Clin. Cancer Res. 18, 6723\u20136731 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1834_CR36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/ajh.23549","volume":"88","author":"IJ Falk","year":"2013","unstructured":"Falk, I. J. et al. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5\u2019-nucleotidase. Am. J. Hematol. 88, 1001\u20131006 (2013).","journal-title":"Am. J. Hematol."},{"key":"1834_CR37","first-page":"329","volume":"48","author":"V Gandhi","year":"1988","unstructured":"Gandhi, V. & Plunkett, W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 48, 329\u2013334 (1988).","journal-title":"Cancer Res."},{"key":"1834_CR38","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1158\/0008-5472.CAN-15-2063","volume":"76","author":"E Griessinger","year":"2016","unstructured":"Griessinger, E. et al. Frequency and dynamics of leukemia-initiating cells during short-term ex vivo culture informs outcomes in acute myeloid leukemia patients. Cancer Res. 76, 2082\u20132086 (2016).","journal-title":"Cancer Res."},{"key":"1834_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","volume":"23","author":"S Takeishi","year":"2013","unstructured":"Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23, 347\u2013361 (2013).","journal-title":"Cancer Cell"},{"key":"1834_CR40","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nature07016","volume":"453","author":"K Ito","year":"2008","unstructured":"Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072\u20131078 (2008).","journal-title":"Nature"},{"key":"1834_CR41","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood.V122.21.1647.1647","volume":"122","author":"ER Lechman","year":"2013","unstructured":"Lechman, E. R. et al. Mir-126 governs human leukemia stem cell quiescence and chemotherapy resistance. Blood 122, 1647 (2013).","journal-title":"Blood"},{"key":"1834_CR42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.1994.12.4.671","volume":"12","author":"E Estey","year":"1994","unstructured":"Estey, E. et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J. Clin. Oncol. 12, 671\u2013678 (1994).","journal-title":"J. Clin. Oncol."},{"key":"1834_CR43","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"1834_CR44","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"1834_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491\u2013498 (2011).","journal-title":"Nat. Genet."},{"key":"1834_CR46","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576 (2012).","journal-title":"Genome Res."},{"key":"1834_CR47","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/bioinformatics\/btp373","volume":"25","author":"DC Koboldt","year":"2009","unstructured":"Koboldt, D. C. et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283\u20132285 (2009).","journal-title":"Bioinformatics"},{"key":"1834_CR48","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"1834_CR49","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01834-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01834-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T23:13:17Z","timestamp":1671750797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01834-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-01834-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]},"assertion":[{"value":"3 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.B. is an employee of Genentech. D.B.\u2019s group was supported by a research grant from Genentech. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1679"}}